Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $102K fell 20.3% year over year, behind the +7.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -17.1% a year.

Context

  • Depreciation & amortization amounted to 5.8% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -20.3% toward the trailing-twelve-month pace of +7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$102K+0.0% QoQ
Last fiscal yearDec 2025
$454K-43.7% YoY
LTMMar 2026
$528K+7.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.3%——
1 year-43.7%——
3-year CAGR-17.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
454K USD
Year-over-year change
-43.7%
4-year CAGR
-16.3%

Depreciation & Amortization vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.3% is the 4th highest of 10, against a peer median of +3.1%.
  • Depreciation & amortization amounts to 6.3% of revenue for ACRS, versus a peer median of 47.7%.
ACRS Competitors
Depreciation & Amortization for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$3.08M USD+50.1%+151.3%—
ALMSAlumis Inc. Common StockLTM Jun 2026$2.65M USD-20.7%+140.9%35.9%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M USD+1.2%+1.2%1.0%
ATTOAttovia Therapeutics, Inc.FY2025$804K USD+156.9%—59.6%
TRAXFirst Tracks Biotherapeutics IncFY2025$559K USD-76.7%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD+7.3%-17.1%6.3%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€311K EUR+214.1%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
IMUXImmunic, Inc.LTM Mar 2026$158K USD+4.6%+29.7%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ACRS) —+3.1%+15.5%47.7%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.